In particular, we demonstrated that a targeted delivery strategy of Paclitaxel using these EphA2 targeting agents is more efficacious than Paclitaxel alone in xenograft models of pancreatic cancer [30]. The gene discussed is EPHA2; the disease is familial pancreatic carcinoma.